Phase II Study Of Iressa [gefitinib] (ZD 1839) In Locally Advanced And/Or Metastatic Synovial Sarcoma Expressing HER1/EGFR1.
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2012
At a glance
- Drugs Gefitinib (Primary)
- Indications Synovial sarcoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 01 Oct 2005 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Sep 2005 New trial record.